Who invested in Glycomine

3 rounds we have observed, with the 8 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

BiotechHealthcare

Funding summaryUpdated 26 Oct 2026

$160Mraised across 3 rounds since 2017, from 3 sources

$12MSeries A$33MSeries B$115MSeries C

Latest round: Series C, $115MApr 2025
Step-upi: 3.5×
Investors: 8 (1 led)

See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

2019202120232025

$12MSeries A$33MSeries B$115MSeries C

First round: Series A, $12M
Biggest round: $115M
Usual gap between rounds: 5.7 years

The rounds

Apr 2025
Series C$115M3 new
Source recorded
Aug 2019
Series B$33M4 new1 returning
- Novo Holdings A/SLead
- Sanderling Ventures
- Mission Bay Capital
- Chiesi Ventures
- Asahi Kasei Pharma Corporation
Reported by FinSMEs
Nov 2017
Series A$12M1 new
- Sanderling Ventures
Reported by FinSMEs

Founders and team

From Glycomine's own website: 2 on the team.

Arthur PappasDirector
Joshua GrassChairperson

Who was in which round

The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.

Series A2017Series B2019Series C2025

Sanderling VenturesNovo Holdings A/SL

Chiesi VenturesAsahi Kasei Pharma Corporation

Everyone who backed them

Sanderling VenturesVC firm2rounds

Novo Holdings A/SGrowth equity1round, led 1

Novo HoldingsVC firm1round

SanofiInvestment firm1round

Mission BioCapitalVC firm1round

Mission Bay CapitalVC firm1round

Chiesi VenturesVC firm1round

Asahi Kasei Pharma Corporationno record of our own yet1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

This firm lists Glycomine as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.